Recombinant human PD-L1 protein (Active) is a Human Fragment protein in the 19 to 238 aa range with >=95% purity, <= 0.005 EU/µg endotoxin level and suitable for SDS-PAGE, Functional studies, ELISA, mass spectrometry and HPLC. The predicted molecular weight of ab2809432 protein is 25.3 kDa.
- Save time and ensure accurate results - use our PD-L1 protein as a control
- Optimal protein bioactivity, stability and reproducibility
- Available in different sizes to fit your experimental needs
F T V T V P K D L Y V V E Y G S N M T I E C K F P V E K Q L D L A A L I V Y W E M E D K N I I Q F V H G E E D L K V Q H S S Y R Q R A R L L K D Q L S L G N A A L Q I T D V K L Q D A G V Y R C M I S Y G G A D Y K R I T V K V N A P Y N K I N Q R I L V V D P V T S E H E L T C Q A E G Y P K A E V I W T S S D H Q V L S G K T T T T N S K R E E K L F N V T S T L R I N T T T N E I F Y C T F R R L D P E E N H T A E L V I P E L P L A H P P N E R
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes - |
Application FuncS | Reactivity Reacts | Dilution info - | Notes - |
Application MS | Reactivity Reacts | Dilution info - | Notes - |
Application HPLC | Reactivity Reacts | Dilution info - | Notes - |
Application sELISA | Reactivity Reacts | Dilution info - | Notes - |
Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed:32929201). The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813410, PubMed:28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).
CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1
Recombinant human PD-L1 protein (Active) is a Human Fragment protein in the 19 to 238 aa range with >=95% purity, <= 0.005 EU/µg endotoxin level and suitable for SDS-PAGE, Functional studies, ELISA, mass spectrometry and HPLC. The predicted molecular weight of ab2809432 protein is 25.3 kDa.
- Save time and ensure accurate results - use our PD-L1 protein as a control
- Optimal protein bioactivity, stability and reproducibility
- Available in different sizes to fit your experimental needs
pH: 7.4
Constituents: 10.26% Trehalose, 0.727% Dibasic monohydrogen potassium phosphate, 0.248% Potassium phosphate monobasic
=95% by HPLC
Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed:32929201).
Belongs to the immunoglobulin superfamily. BTN/MOG family.
Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation (PubMed:28813410). Ubiquitinated by MARCHF8; leading to degradation (PubMed:34183449). Deubiquitinated by USP22; leading to stabilization (PubMed:31399419).
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Ensure the validity of your result using our recombinant human PD-L1 protein ab280943 as a control.
The ab280943 PD-L1 protein is sourced from HEK293 cells and can be used as a positive control in SDS-PAGE, mass spectrometry and HPLC. Analyze your PD-L1 ELISA data using the ab280943 protein to generate and plot a standard curve.
Check out our protein gel staining guide for SDS-PAGE here
Check out our ELISA protocol for more information here.
Premium Bioactive Protein range
The ab280943 PD-L1 protein is part of the premium bioactive protein range which are ideal for preclinical cell culture and functional studies. These recombinant proteins are of the highest activity, purity, and consistency, meeting rigorous biophysical characterization.
More premium bioactive proteins can be found here
PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.
PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.
PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Functional analysis of an280943.
Fully biologically active measured by its ability to inhibit anti-CD3 and anti-CD8 antibody induced T-cell expansion. ED50 for this effect is ≤500 ng/mL with a specific activity of 0.2 x 104 units/mg.
Cell based assay testing is performed on the first lot of protein only and is provided as a reference for protein activity; subsequent lots of protein must pass all biophysical quality control parameters that meet the same parameters as the first lot.
Lot: GR3381126-2
Sandwich ELISA - Recombinant human PD-L1 protein standard curve.
Background subtracted standard curve using Human/Monkey PD-L1 [28-8] Antibody Pair - BSA and Azide free (Human/Monkey PD-L1 [28-8] Antibody Pair - BSA and Azide free ab253485) and Recombinant human PD-L1 protein (Active) (ab280943) in sandwich ELISA. The ELISA was performed using the components of the corresponding SimpleStep® kit, which uses the same antibody pair with a different formulation and format.
SDS-PAGE analysis of ab280943.
Mass determination by ESI-TOF.
Predicted MW is 25250.68 Da (+/- 10 Da by ESI-TOF). Observed MW is 25097.90 Da. M-100 due to loss of C-terminal arginine.
HPLC analysis of ab280943.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com